A Phase 3 interventional study of Paroxetine CR in Depressive Disorder, Major and Major Depressive Disorder (MDD), sponsored by GlaxoSmithKline. Completed at 46 sites in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2016-09-01.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Major Depressive Disorder (MDD) Study in Elderly Outpatients
4,845 studies on the registry are indexed under Depressive Disorder; 514 are open to participants now.
This study's enrollment of 560 is above the median of 80 across 3,999 interventional studies indexed under Depressive Disorder.
Browse Depressive Disorder studies →GlaxoSmithKline is the lead sponsor of 3,562 studies on the registry; 117 are open to participants now.
Of its 258 completed or terminated interventional studies of FDA-regulated products, 232 (90%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Change from baseline to the week 10 last observation carried forward endpoint in the 17-item HAM-D total score.
Time frame: 10 Weeks
Mean change from baseline in HAM-D item 1; Mean change from baseline in the CGI severity of illness score at study endpoint; Percentage of patients with HAM-D total score less than or equal to 7.
Time frame: 10 Weeks
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
GlaxoSmithKline